Form SC 13D - General Statement of Acquisition of Beneficial Ownership:
SEC Accession No. 0000947871-24-000805
Filing Date
2024-10-17
Accepted
2024-10-17 16:16:24
Documents
2
Group Members
ORBIMED ADVISORS ISRAEL II LTDORBIMED CAPITAL GP VIII LLCORBIMED ISRAEL GP II, L.P.

Document Format Files

Seq Description Document Type Size
1 SCHEDULE 13D ss4005698_sc13d.htm SC 13D 135291
2 JOINT FILING AGREEMENT ss4005698_ex9901.htm EX-99.1 7283
  Complete submission text file 0000947871-24-000805.txt   144245
Mailing Address 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022
Business Address 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022 (212) 739-6400
ORBIMED ADVISORS LLC (Filed by) CIK: 0001055951 (see all company filings)

EIN.: 133976876 | State of Incorp.: DE
Type: SC 13D

Mailing Address 890 WINTER STREET, SUITE 200 WALTHAM MA 02451
Business Address 890 WINTER STREET, SUITE 200 WALTHAM MA 02451 781-208-2466
Upstream Bio, Inc. (Subject) CIK: 0002022626 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D | Act: 34 | File No.: 005-94651 | Film No.: 241377773
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)